SUNITINIB
Manner of administration:Oral
Restriction
Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine
tumour (pNET)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 2 | DPMQ: $524.33 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17862)
Indication: Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine
tumour (pNET)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 5 | DPMQ: $524.33 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17789)
Indication: Metastatic or unresectable malignant gastrointestinal stromal tumour
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 1 | DPMQ: $524.33 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
Manner of administration:Oral
Restriction (Streamlined authority code: 11878)
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 1 | DPMQ: $524.33 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
Manner of administration:Oral
Restriction (Streamlined authority code: 17856)
Indication: Stage IV clear cell variant renal cell carcinoma (RCC)
Treatment phase: Continuing treatment beyond 3 months
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 3 | DPMQ: $524.33 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||
Manner of administration:Oral
Restriction
Indication: Metastatic or unresectable malignant gastrointestinal stromal tumour
Treatment phase: Initial treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 28 | # of repeats: 1 | DPMQ: $524.33 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||